• 1
    Doggrell SA. Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs. 2004; 13: 86574.
  • 2
    Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2004; 22: 2754.
  • 3
    Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sar-pogrelate. J Pharmacol Exp Therap. 1999; 290: 147581.
  • 4
    Saini HK, Sharma SK, Zahradka P, Kumamoto H, Takeda N, Dhalla NS. Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate. Can J Physiol Pharmacol. 2003; 81: 105663.
  • 5
    Sharma SK, Del Rizzo DF, Zahradka P, Bhangu SK, Werner JP, Kumamoto H, Takeda N, Dhalla NS. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells. Implications for long-term graft patency. Ann Thorac Surg. 2001; 71: 185664.
  • 6
    Brasil D, Temsah RM, Kumar K, Kumamoto H, Takeda N, Dhalla NS. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J Cardiovasc Pharmacol Ther. 2002; 7: 539.
  • 7
    Temsah RM, Kumamoto H, Takeda N, Dhalla NS. Sarpogrelate diminishes changes in energy stores and ultrastruc-ture of the ischemic-reperfused rat heart. Can J Physiol Pharmacol. 2001; 79: 7617.
  • 8
    Nebigil CG, Maroteaux L. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation. 2003; 108: 9028.
  • 9
    Dhalla NS, Shao Q, Panagia V. Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev. 1998; 2: 26172.
  • 10
    Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Therapeut. 2006; 11: 3145.
  • 11
    Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999; 14: 6371.
  • 12
    Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, Ishii K, Miwa K. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J. 2003; 145: E16.
  • 13
    Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999; 100: 216.
  • 14
    Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol. 2002; 34: 84757.
  • 15
    Shao Q, Ren B, Saini HK, Netticadan T, Takeda N, Dhalla NS. Sarcoplasmic retic-ulum Ca2+-transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol. 2005; 288: H167482.
  • 16
    Saini HK, Shao Q, Musat S, Takeda N, Tappia PS, Dhalla NS. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol. 2005; 144: 20211.
  • 17
    Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quanti-tation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 35867.
  • 18
    Wang J, Guo X, Dhalla NS. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta. 2004; 1690: 17784.
  • 19
    Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losar-tan. Mol Cell Biochem. 2003; 254: 16372.
  • 20
    Liu X, Takeda N, Dhalla NS. Troponin I phosphorylation in heart homogenate from diabetic rat. Biochim Biophys Acta. 1996; 1316: 7884.
  • 21
    Wood MA, Hess ML. Long term oral therapy of congestive heart failure with phos-phodiesterase inhibitors. Am J Med Sci. 1989; 297: 10513.
  • 22
    Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T, Mori H, Terada N, Hori M. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation. 2001; 104: 70510.
  • 23
    Barta J, Sanganalmath SK, Sethi R, Kumamoto H, Takeda N, Edes I, Dhalla NS. Antithrombotic agents sarpogrelate and cilostazol differentially affect ventricular arrhythmias and survival in rats. Exp Clin Cardiol. 2006; 11: 246 (Abstract).
  • 24
    Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, De Breyne B. Evaluation of the effect of phosphodi-esterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. J Clin Pharmacol. 1994; 46: 1916.
  • 25
    Pieske B, Maier LS, Bers DM, Hasenfuss G. Ca2+ handling and sarcoplasmic reticu-lum Ca2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999; 85: 3846.
  • 26
    Yano M, Ikeda Y, Matsuzaki M. Altered intracellular Ca2+ handling in heart failure. J Clin Invest. 2005; 115: 55664.
  • 27
    Zhang XE, Musch TI, Zellis R, Cheung JY. Effects of impaired Ca2+ homeostasis on contraction in post infarction myocytes. J Appl Physiol. 1999; 86: 94350.
  • 28
    Afzal N, Dhalla NS. Differential changes in left and right ventricular SR Ca2+ transport in congestive heart failure. Am J Physiol. 1992; 262: H86874.
  • 29
    Netticadan T, Temsah RM, Kawabata K, Dhalla NS. Sarcoplasmic reticulum Ca2+/Calmodulin-dependent protein kinase is altered in heart failure. Circ Res. 2000; 86: 596605.
  • 30
    Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004; 113: 72736.
  • 31
    Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Chronic phospholamban-sar-coplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999; 99: 31322.
  • 32
    Hajjar RJ, Del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res. 2000; 86: 61621.
  • 33
    Kuschel M, Karczewski P, Hempel P, Schlegel WP, Krause EG, Bartel S. Ser16 prevails over Thr17 phospholamban phos-phorylation in the beta-adrenergic regulation of cardiac relaxation. Am J Physiol. 1999; 276: H162533.
  • 34
    Van Der Velden J, Papp Z, Zaremba R, Boontje NM, De Jong JW, Owen VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJ. Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003; 57: 3747.
  • 35
    Bodor GS, Oakeley AE, Allen PD, Crimmins DL, Ladenson JH, Anderson PA. Troponin I phosphorylation in the normal and failing adult human heart. Circulation. 1997; 96: 1495500.
  • 36
    Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995; 76: 102835.
  • 37
    Haddad F, Bodell PW, Qin AX, Giger JM, Baldwin KM. Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching. J Biol Chem. 2003; 278: 371328.
  • 38
    VanBuren P, Harris DE, Alpert NR, Warshaw DM. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res. 1995; 77: 43944.
  • 39
    Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987; 61: 53947.
  • 40
    Ikeda K, Tojo K, Tokudome G, Hosoya T, Harada M, Nakao K. The effects of sar-pogrelate on cardiomyocyte hypertrophy. Life Sci. 2000; 67: 29916.
  • 41
    Brattelid T, Qvigstad E, Birkeland JA, Swift F, Bekkevold SV, Krobert KA, Sejersted OM, Skomedal T, Osnes JB, Levy FO, Sjaastad I. Serotonin responsiveness through 5-HT(2A) and 5-HT(4) receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol. 2007; 43: 76779.
  • 42
    Sweet CS, Ludden CT, Stabilito II, Emmert SE, Heyse JF. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol. 1988; 147: 2937.
  • 43
    Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodi-esterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol. 2005; 514: 2018.
  • 44
    Movsesian MA. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail. 2003; 9: 47580.
  • 45
    Dhalla NS, Afzal A, Beamish RE, Naimark B, Takeda N, Nagano M. Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol. 1993; 9: 87387.